Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
37
OTLC Quote, Financials, Valuation and Earnings
Last price:
$0.10
Seasonality move
:
-0.41%
Day range:
$0.09 - $0.10
52-week range:
$0.02 - $0.11
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.59x
Volume:
118K
Avg. volume:
231.5K
1-year change:
190.85%
Market cap:
$41.5M
Revenue:
--
EPS (TTM):
-$0.00
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Oncotelic Therapeutics, Inc. has 4164.39% upside to fair value with a price target of -- per share.
OTLC vs. S&P 500
-
Over the past 5 trading days, Oncotelic Therapeutics, Inc. has underperformed the S&P 500 by -3.72% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Oncotelic Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Oncotelic Therapeutics, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Oncotelic Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Oncotelic Therapeutics, Inc. has grown year-over-year earnings for 4 quarters straight. In the most recent quarter Oncotelic Therapeutics, Inc. reported earnings per share of -$0.00.
Enterprise value:
54.7M
EV / Invested capital:
2.42x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.04x
EV / Free cash flow:
-77.62x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-7.12%
Net Income Margin (TTM):
--
Return On Equity:
-25.13%
Return On Invested Capital:
-8.93%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $70K | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$903K | -$458K | -$689.5K | -$80.8K | -$491K | |
| EBITDA | -$903K | -$458K | -$689.5K | -$80.8K | -$491K | |
| Diluted EPS | -$0.03 | -$0.01 | -$0.00 | -$0.01 | -$0.00 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $188.8K | $312K | $365.5K | $239K | $1.6M | |
| Total Assets | $23.2M | $40.2M | $30.1M | $26.8M | $28.2M | |
| Current Liabilities | $14.8M | $16.2M | $17.1M | $16.4M | $20.1M | |
| Total Liabilities | $14.8M | $16.2M | $18M | $18.7M | $20.1M | |
| Total Equity | $8.4M | $24M | $12.1M | $8.1M | $8.1M | |
| Total Debt | -- | -- | $899.1K | $2.3M | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$1M | -$1M | -$704K | -$143.2K | -$307K | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $1M | $890K | $964K | $220K | $628K | |
| Free Cash Flow | -$1M | -$1M | -$704.1K | -$143.2K | -$307K | |
OTLC
Sector
Market Cap
$41.5M
$28.5M
Price % of 52-Week High
85.27%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-0.91%
-1.33%
1-Year Price Total Return
190.85%
-20.32%
Beta (5-Year)
-0.758
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.09
200-day SMA
Buy
Level
$0.06
Bollinger Bands (100)
Buy
Level
0.05 - 0.09
Chaikin Money Flow
Sell
Level
-44.9M
20-day SMA
Sell
Level
$0.09
Relative Strength Index (RSI14)
Buy
Level
51.08
ADX Line
Sell
Level
16.9
Williams %R
Neutral
Level
-33.1269
50-day SMA
Sell
Level
$0.09
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Neutral
Level
40.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.455)
Sell
CA Score
(Annual)
Level (-1.1708)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (16.5434)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Oncotelic Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of anti-vascular therapeutics for patients with cancer and sight-threatening eye diseases. It also develops OT-101 for various cancers and COVID-19, Artemisinin for COVID-19 and AI technologies for clinical development and manufacturing. The company was founded in 1988 and is headquartered in Agoura Hills, CA.
Stock Forecast FAQ
In the current month, OTLC has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The OTLC average analyst price target in the past 3 months is --.
-
Where Will Oncotelic Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Oncotelic Therapeutics, Inc. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Oncotelic Therapeutics, Inc.?
Analysts are divided on their view about Oncotelic Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Oncotelic Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to --.
-
What Is Oncotelic Therapeutics, Inc.'s Price Target?
The price target for Oncotelic Therapeutics, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is OTLC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Oncotelic Therapeutics, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of OTLC?
You can purchase shares of Oncotelic Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Oncotelic Therapeutics, Inc. shares.
-
What Is The Oncotelic Therapeutics, Inc. Share Price Today?
Oncotelic Therapeutics, Inc. was last trading at $0.10 per share. This represents the most recent stock quote for Oncotelic Therapeutics, Inc.. Yesterday, Oncotelic Therapeutics, Inc. closed at $0.09 per share.
-
How To Buy Oncotelic Therapeutics, Inc. Stock Online?
In order to purchase Oncotelic Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get OTLC Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
OTLC
Sector
P/E ratio
--
23.75x
PEG ratio
-0.04x
-0.01x
P/B ratio
4.59x
1.83x
Price / LTM sales
--
1.60x
Growth Metrics
OTLC
Sector
Revenue growth
--
4.85%
Earnings growth
69.14%
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
--
-$0.20
Profitability
OTLC
Sector
Profitability FY 2024
--
$3.6M
Return on invested capital
-8.93%
-30.98%
Return on assets
-7.12%
-27.62%
Return on equity
-25.13%
-36.69%
Earnings Date
Last Earnings Date
Nov
14
Next Earnings Date
Dec
8
Estimated Next Earnings Date
Mar
9
Balance Sheet
OTLC
Sector
Total cash
$429K
$27.2M
Short term investments
--
$25.7M
Total assets
$26.7M
$79.7M
Long term debt
--
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 65.66% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 9.94% over the past day.
Sell
13
PSN alert for Dec 8
Parsons Corp. [PSN] is down 4.41% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
